Cargando…
The challenge of targeting metastasis
Metastases that are resistant to conventional therapy are the major cause of death from cancer. In most patients, metastasis has already occurred by the time of diagnosis. Thus, the prevention of metastasis is unlikely to be of therapeutic benefit. The biological heterogeneity of metastases presents...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4661188/ https://www.ncbi.nlm.nih.gov/pubmed/26328524 http://dx.doi.org/10.1007/s10555-015-9586-9 |
_version_ | 1782402935159783424 |
---|---|
author | Fidler, Isaiah J. Kripke, Margaret L. |
author_facet | Fidler, Isaiah J. Kripke, Margaret L. |
author_sort | Fidler, Isaiah J. |
collection | PubMed |
description | Metastases that are resistant to conventional therapy are the major cause of death from cancer. In most patients, metastasis has already occurred by the time of diagnosis. Thus, the prevention of metastasis is unlikely to be of therapeutic benefit. The biological heterogeneity of metastases presents a major obstacle to treatment. However, the growth and survival of metastases depend on interactions between tumor cells and host homeostatic mechanisms. Targeting these interactions, in addition to the tumor cells, can produce synergistic therapeutic effects against existing metastases. |
format | Online Article Text |
id | pubmed-4661188 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-46611882015-12-04 The challenge of targeting metastasis Fidler, Isaiah J. Kripke, Margaret L. Cancer Metastasis Rev Non-Thematic Review Metastases that are resistant to conventional therapy are the major cause of death from cancer. In most patients, metastasis has already occurred by the time of diagnosis. Thus, the prevention of metastasis is unlikely to be of therapeutic benefit. The biological heterogeneity of metastases presents a major obstacle to treatment. However, the growth and survival of metastases depend on interactions between tumor cells and host homeostatic mechanisms. Targeting these interactions, in addition to the tumor cells, can produce synergistic therapeutic effects against existing metastases. Springer US 2015-09-02 2015 /pmc/articles/PMC4661188/ /pubmed/26328524 http://dx.doi.org/10.1007/s10555-015-9586-9 Text en © The Author(s) 2015 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Non-Thematic Review Fidler, Isaiah J. Kripke, Margaret L. The challenge of targeting metastasis |
title | The challenge of targeting metastasis |
title_full | The challenge of targeting metastasis |
title_fullStr | The challenge of targeting metastasis |
title_full_unstemmed | The challenge of targeting metastasis |
title_short | The challenge of targeting metastasis |
title_sort | challenge of targeting metastasis |
topic | Non-Thematic Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4661188/ https://www.ncbi.nlm.nih.gov/pubmed/26328524 http://dx.doi.org/10.1007/s10555-015-9586-9 |
work_keys_str_mv | AT fidlerisaiahj thechallengeoftargetingmetastasis AT kripkemargaretl thechallengeoftargetingmetastasis AT fidlerisaiahj challengeoftargetingmetastasis AT kripkemargaretl challengeoftargetingmetastasis |